Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03536767 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Open-Label Study of AG10 in Patients with Cardiomyopathy

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study Identification, Study Status, Oversightv10
  2. Primary and study completion dates: Jul 2023 to Jul 2027 Study description expanded, about 15 wordsv9 Show 1 more changeShow less
    • Study description expanded, about 15 words

    See this version in full on ClinicalTrials.gov ↗

  3. Trial status: Enrolling by Invitation to Active, Not Recruitingv8
  4. 2 versions Re-verified since Apr 12, 2019, no change to tracked fieldsv6-v7
  5. Primary and study completion dates: Dec 2018 to Jul 2023 Start date changed from estimate of Jul 2018 to Aug 8, 2018 · Eligibility criteria shortened, about 148 words · Secondary endpoints: details revised at 4 of 4 entries · 1 morev5 Show 4 more changesShow less
    • Start date changed from estimate of Jul 2018 to Aug 8, 2018
    • Eligibility criteria shortened, about 148 words
    • Secondary endpoints: details revised at 4 of 4 entries
    • Study description expanded, about 9 words

    See this version in full on ClinicalTrials.gov ↗

Show 3 earlier versionsHide 3 earlier versions
  1. Primary and study completion dates: May 2020 to Dec 2018 Enrollment target: 45 to 55 · Start date: Jun 2018 to Jul 2018 · Secondary endpoints: details revised at 4 of 4 entries · 1 morev4 Show 4 more changesShow less
    • Enrollment target: 45 to 55
    • Start date: Jun 2018 to Jul 2018
    • Secondary endpoints: details revised at 4 of 4 entries
    • Study description expanded, about 7 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study sites: 12 to 9v3
  3. Study title shortened, about 1 wordv2 See this version in full on ClinicalTrials.gov ↗
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This prospective, multicenter open-label study will evaluate the long-term safety, tolerability, PK and PD of AG10 administered on a background of stable heart failure therapy.
Trial Details
NCT Number NCT03536767
Lead Sponsor Eidos Therapeutics, a BridgeBio company
Conditions Amyloid Cardiomyopathy
Enrollment 55 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov